ISACA Expands European Presence With New Office in Dublin
9.9.2022 15:30:00 EEST | Business Wire | Press release
As a result of the continued growth and development over the last 50 years, ISACA, the global professional association advancing individuals and organizations in their pursuit of digital trust, is expanding its international reach and opening a new office in Dublin—its first European office.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005075/en/
Chris Dimitriadis, Chief Global Strategy Officer at ISACA (Photo: Business Wire)
ISACA´s success is defined by the passion, hard work and commitment of its more than 165,000 members in more than 180 countries worldwide. In Europe, the organization has over 30,000 members working in information and cyber security, assurance, governance, risk and privacy from different industries such as Banking & Finance, Government, Telecommunications, Engineering, Public Accounting, Education, Retail, Health, FMCG, Automotive, Utilities, Food & Beverage among others.
ISACA in Europe combines the strength and scale of a large, multi-national organization with an expert, local knowledge of the market and professional communities ISACA serves. The new office intends to facilitate cooperation between European regions, chapters and members and strengthen ISACA’s capacity to collaborate with key public and private stakeholders, as well as enterprises and academia.
“Our expanded regional presence in Europe will provide services dedicated to Europe and help extend our global reach and impact,” said ISACA CEO David Samuelson. “ISACA is both a global and a local organization, and we want to serve our professional communities where they live and work. We are very excited to have a stronger local presence in Europe to better partner with European government, enterprises, universities and our members to advance digital trust.”
The office and ISACA’s new team members in Europe will build on the strong ties that already exist between regions by promoting investment, synergies and economic opportunities to benefit members and enterprises.
Ireland’s Minister of State for eGovernment Ossian Smyth said, “We welcome ISACA’s commitment and investment into Ireland. As we continue to develop Ireland as a European hub for the digital economy and as a cyber centre of excellence, it is crucial to continue to build an expert and diverse specialist ecosystem. ISACA’s pre-eminent global work on talent development, building the cyber profession and developing tools and frameworks to underpin the next phase of technology adoption in a safe and transparent manner, will be a boost to our tech scene. We look forward to ongoing cooperation with ISACA in improving cybersecurity preparedness and resilience.”
ISACA’s European presence is led by Chris Dimitriadis, Chief Global Strategy Officer at ISACA. Dimitriadis has deep industry and ISACA experience, having served as ISACA board chair and as a past chief information security officer at a global organization.
“ISACA has a long history in Europe, and we are incredibly proud of our chapters, volunteers, members and partners in the region,” said Dimitriadis. “We are excited to strengthen our support in the communities that we serve by establishing a team of highly experienced and reputable European professionals and by opening our first office in Dublin that will strategically coordinate and support our 45 chapters in Europe and our business, government and academic partners.”
ISACA, established in 1969, is widely known for its globally recognized certifications, including Certified Information Systems Auditor (CISA) and Certified Information Security Manager (CISM), and its industry-leading frameworks, including COBIT. Additional information is at www.isaca.org/.
About ISACA
ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA is a global professional association and learning organization that leverages the expertise of its more than 165,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality. It has a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for underresourced and underrepresented populations.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005075/en/
Contact information
Esther Almendros, ealmendros@isaca.org, T: +1 847-660-5777, M: +34 692 669 722
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
